, Columnist
Illumina CEO’s Grail Hunt Runs Into a Quagmire
Francis deSouza has been fighting regulators and shareholders for three years to hold on to a flawed deal. How much longer can that last?
Illumina CEO Francis deSouza is fighting regulators and shareholders to hold on to Grail.
Photographer: Stefan Wermuth/Bloomberg
This article is for subscribers only.
Sometimes bad deals are apparent from the beginning. More often, they are discovered in hindsight after chief executive officers at least have the opportunity to try to integrate them and make them work.
Francis deSouza, the CEO of biotechnology giant Illumina Inc., seems unlikely to even get that chance.